Metabolic syndrome and atherosclerosis

Cover Page

Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Cardiovascular diseases are becoming the leading cause of morbidity and mortality. Scientific and technological progress has had a negative impact on human life, by limiting physical activity while allowing high mobility, by increasing the caloric value of foods and changing eating habits, and by causing chronic stress. Among the natural consequences of scientific and technological progress is the great number of people suffering from metabolic disturbances, which has led to the separation of a special group of «metabolic» diseases resulting in accelerated development of atherosclerosis. Here we review the evidence for the epidemic character of metabolic syndrome incidence. In particular, the signs of metabolic syndrome in children and adolescents, such as mild blood pressure elevation, small increase of body mass and dyslipidemia, may seem virtually harmless, but later lead to atherosclerotic lesions.

About the authors

N. A. Belyakov

Saint Petersburg Medical Academy of Postgraduate Education

Author for correspondence.
Email: shabanov@mail.rcom.ru

академик РАМН

Russian Federation, Saint Petersburg

S. Yu. Chubriyeva

Saint Petersburg Medical Academy of Postgraduate Education

Email: shabanov@mail.rcom.ru
Russian Federation, Saint Petersburg

References

  1. Алмазов В. А., Благосклонная Я. В., Шляхто Е. В. и др. Метаболический сердечно-сосудистый синдром. СПб.: СПбГМУ, 1999. 208 с.
  2. Беляков Н. А., Сеидова Г. Б., Чубриева С. Ю., Глухов Н. В. Метаболический синдром у женщин. СПб.: Издательский дом СПбМАПО, 2005. 440 с.
  3. Barker D. J. P., Hales С. N., Fall С H D. et al. Type 2 (non-insulin-dependent) diabetes melli- tus, hypertension and hyperlipidaemia (syndrome X): relation to reduced fetal growth // Diabetologia. 1993. Vol. 3 6. P. 62-67.
  4. В avenholm P, Karpe F, Proudler A. et al. Association of insulin and insulin propeptides with an atherogenic lipoprotein phenotype // Metabolism. 1995. Vol. 44. P. 1481-1488.
  5. Boden G. Role of fatty acids in the pathogenesis of insulin resistance and NIDDM // Diabetes. 1997. Vol. 46. P. 3-10.
  6. Bosse Y., Chagnon Y. C., Despres J. P et al. Compendium of genome-wide scans of lipid-related phenotypes: adding a new genome-wide search of apolipoprotein levels // J. Lipid. Res. 2004. Vol. 45. P. 2174-2184.
  7. Bosse Y, Perusse L., Despres J. P et al. Evidence for a major quantitative trait locus on chromosome 17q21 affecting low-density lipoprotein peak particle diameter // Circulation. 2003. Vol. 107. P. 2361-2368.
  8. Bruun J. M., Lihn A. S., Madan A. K. et al. Higher production of IL-8 in visceral vs. subcutaneous adipose tissue. Implication of nonadipose cells in adipose tissue // Am. J. Physiol. Endocrinol. Metab. 2004. Vol. 286. № 1. P. E8-E13.
  9. Camus J. P Goutte, diabete, hyperlipemie: un trisyndrome metabolique // Rev. Rhumat. 1966. Vol. 33. P. 10-14.
  10. Chan D. S., Wats G. F, TW Ng. et al. Adiponectin and other adipocytokines as predictors of markers of triglyceride-rich lipoprotein metabolism // Clin. Chern. 2005. Vol. 51. № 3. P. 578-585.
  11. Chan J. C. N., Tong P. C Y., Critchley J. A. J. H. The insulin resistance syndrome: mechanisms of clustering of cardiovascular risk // Semin. Vase. Med. 2002. Vol. 2. № 1. P. 45-57.
  12. Cook S., Weitzman M., Auinger R et al. Prevalence of a metabolic syndrome phenotype in adolescents: finding from the third National Health and Nutrition Examination Survey, 1988-1994 // Arch. Pediatr. Adolesc. Med. 2003. Vol. 157. P. 821-827.
  13. Correia M. L. G., Haynes W. G., Rahmouni K. et al. The concept of selective leptin resistance: evidence from Agouti yellow obese mice [Pathophysiology] // Diabetes. 2002. Vol. 51. № 2. P. 439-442.
  14. Daae L. N, Kierulf R, Landaas S. et al. Cardiovascular risk factors interaktive of lipids, coagulation and fibrinolysis // Scandinavian J. of clinical and laboratory investigation. Suppl. 1993. Vol. 215. P. 19-27.
  15. Descovich G. C, Benassi B., Cancelli V. etal. An epidemic view of the plurimetabolic syndrome // Diabetes, Obesity and Hyperlipidemias. V. The Plurimetabolic Syndrome / Crepaleli G., Tiengo A., Manzato E. (eds). Amsterdam. Netherlands. Elsevier Science. 1993. P. 31-39.
  16. Engeli S., Sharma A. M. Role of adipose tissue for cardiovascular-renal regulation in health and disease // Homi. Metab. Res. 2000. Vol. 32. P. 485-499.
  17. Farooqi I. S., Jebb S. A., Langmack G. et al. Effects of recombinant leptin therapy in a child with congenital leptin deficiency // N. Engl. J. Med. 1999. Vol. 341. P. 879-884.
  18. Flier J. S., Lowell B., Napolitano A. et al. Adipsin: regulation and dysregulation in obesity and other metabolic states // Recent Prog. Horm. Res. 1989. Vol. 45. P. 567-580.
  19. Fontbonne A., Charles М. A., Thibault N. et al. Hyperinsulinemia as a predictor of coronary heart disease mortality in a healthy population. The Paris Prospective Study, 15-year follow up // Diabetologia. 1991. Vol. 34. P. 356-361.
  20. Ford E. S., Giles W. H., Dietz W. H. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey // JAMA. 2002. Vol. 287. № 3. P. 356-359.
  21. Fruhbeck G., Jebb S. A., Prentice A. M. Leptin: physiology and pathophysiology // Clin. Physiol. 1998. Vol. 18. P. 399-419.
  22. Golay A., Zech L., Shi M. Z. et al. High density lipoprotein (HDL) metabolism in non-insulin- dependent diabetes mellitus: measurement of HDL turnover using tritiated HDL // J. Clin. Endocrinol. Metab. 1987. Vol. 65. P. 512-518.
  23. Groop L., Orho-Melander M. The dysmetabolic syndrome // J. Intern. Med. 2001. Vol. 250. P. 105-120.
  24. Haffner S. M. Insulin and blood pressure in the San Antonio Heart Study: A review // Cardio- vasc. Risk Factors. 1993. Vol. 1. P. 18-27.
  25. Haffner S. M., Miettinen H., Муккапеп L., Stern M. P. Leptin concentrations are associated with higher proinsulin and insulin concentrations but a lower proinsulin/insulin ratio in non-diabe- tic subjects // Int. J. Obes. 1998. Vol. 22. P. 899-905.
  26. Hanefeld M., Leonhardt W. Das Metabolische Syndrom // Dtsch. Gesundh. Wesen. 1981. Vol. 36. P. 545-551.
  27. Heid H. W, Moll R., Schwetlick I. et al. Adipophilin is a specific marker of lipid accumulation in diverse cell types and diseases // Cell Tissue Res. 1998. Vol. 294. № 2. P. 309-321.
  28. Hotamisligil G. S., Shargill N. S., Spiegelman В. M. Adipose expression of tumor necrosis factoralpha: direct role in obesity-linked insulin resistance // Science. 1993. Vol. 259. P. 87-91.
  29. Iniguez G., Soto N., Avila A. et al. Adiponectin levels in the first two years of life in a prospective cohort: relations with weight gain, leptin levels and insulin sensitivity // J. Clin. Endocrinol. Metab. 2004. Vol. 89. № 11. P. 5500-5503.
  30. Isomaa B., Almgren P., Tuomi T. et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome // Diabetes Care. 2001. Vol. 24. № 4. P. 683-689.
  31. Jahnke K, Daweke H, Liebermeister H. et al. Hormonal and metabolic aspects of obesity in humans // Proceedings of the sixth congress of the International Diabetes Federation. 1967 / Ostmann J. (ed). Excerpta Medica. 1969. P. 533-539.
  32. Kannel W. B., Castelli W. P, McNamara M. P The coronary profile: 12-year follow-up in Fra- mingam Study // J. Occup. Med. 1987. Vol. 9. P. 611-619.
  33. Kaplan N. M. The deadly quartet: upper-body obesity, glucose intolerance, hypertriglyceridemia, and hypertension // Arch. Intern. Med. 1989. Vol. 149. P. 1514-1520.
  34. Karelis A. D., St-Pierre D. H., Conus F. et al. Metabolic and body composition factors in subgroups of obesity: what do we know? // J. Clin. Endocrinol. Metab. 2004. Vol. 89. P. 2569-2575.
  35. Kario K, Nafo N, Kayaba К et al. Characteristics of the insulin resistance syndrome in a Japanese population. The Jichi Medical School Cohort Study // Atheroscler. Throm. Vase. Biol. 1996. Vol. 16. P. 270-274.
  36. Kim Y. B., Uotani S., Pierroz D. D. et al. In vivo administration of leptin activates signal transduction directly in insulin-sensitive tissues: overlapping but distinct pathways from insulin // Endocrinology. 2000. Vol. 141. P. 2328-2339.
  37. Klein В. E. K, Klein R.t Lee К E. Components of the metabolic syndrome and risk of cardiovascular disease and diabetes in Beaver Dam // Diabetes Care. 2002. Vol. 25. № 10. P. 1790-1794.
  38. Kolaczynski J. W., Nyce M. R., Considine R. V. et al. Acute and chronic effects of insulin on leptin production in humans: studies in vivo and in vitro // Diabetes. 1996. Vol. 45. P. 699-701.
  39. Kubota N, Terauchi Y, Yamauchi T et al. Disruption of adiponectin causes insulin resistance and neointimal formation // J. Biol. Chern. 2002. Vol. 277. P. 25863-25866.
  40. Kumada M., Kihara S., Sumitsuji S. et al. Association of hypoadiponectinemia with coronary artery disease in men // Arterioscler. Thromb. Vase. Biol. 2003. Vol. 23. P. 85-89.
  41. Kumada M., Kihara S., Sumitsuji S. et al. Association of hypoadiponectinemia with coronary artery disease in men // Arterioscler. Thromb. Vase. Biol. 2004. Vol. 23. P. 85-89.
  42. Laakso M., Sarlund H, Salonen R. et al. Asymptomatic atherosclerosis and insulin resistance // Arterioscler. Thromb. 1991.Vol. 11. P. 1068-1076.
  43. Lamarche B., Cantin B., Mauriege P. et al. Variability in the risk of ischemic heart disease associated with moderate hypertriglyceridemia. Quebec Cardiovascular Study // Circulation. 1999. Vol. 100. P. 3900 (Suppl.).
  44. Larsson H., Elmstahl S., Ahren B. Plasma leptin levels correlate to islet function independently of body fat in postmenopausal women // Diabetes. 1996. Vol. 45. P. 1580-1584.
  45. Lehto S., Ronnemaa T., Haffner S. et al. Dislipidemia and hyperglycemia predict coronary heart disease events in middle-aged patients with NIDDM//Diabetes. 1997. Vol. 46. P. 1354-1359.
  46. Leibowitz S. F. Specificity of hypothalamic peptides in the control of behavioral and physiological processes // Ann. N. Y. Acad. Sci. 1994. Vol. 739. P. 12-35.
  47. Lindsay R. S., Funahashi T., Hanson R. L. et al. Adiponectin and development of type 2 diabetes in the Pima Indian population // Lancet. 2002. Vol. 360. P. 57-58.
  48. Lord G. M., Matarese G., Howard J. K. et al. Leptin modulates the T-cell immune response and reverses starvation-induced immunosuppression//Nature. 1998. Vol. 3 94. P. 897-901.
  49. Maison P., Byrne C. D., Hales C. N. et al. Do different dimensions of the metabolic syndrome change together over time? Evidence supporting obesity as the central feature // Diabetes Care. 2001. Vol. 24. № 10. P. 1758-1763.
  50. Manne J., Argeson A. C., Siracusa L. D. Mechanisms for the pleiotropic effects of the agouti gene // Proc. Natl. Acad. Sci. USA. 1995. Vol. 92. № 11. P. 4721-4724.
  51. Matsuzawa Y Adipocytokines and metabolic syndrome // Seminars in vascular medicine. 2005. Vol. 5. № 1. P. 34-39.
  52. Matsuzawa Y M., Funahashi T, Kihara S., Shimomura L Adiponectin and metabolic syndrome // Arterioscler. Thromb. Vasc. Med. 2004. Vol. 24. P. 29-34.
  53. Mauricio D., Mandrup-Poulsen T. Apoptosis and the pathogenesis of IDDM: a question of life and death // Diabetes. 1998. Vol. 47. № 10. P. 1537-1543.
  54. McNeill A. M., Rosamond W. D., Girman C. J. et al. The metabolic syndrome and 11 -year risk of incident cardiovascular disease in the atherosclerosis risk in Communities Study // Diabetes Care. 2005. Vol. 2 8. № 2. P. 3 85-3 90.
  55. McTernan P G.f McTernan C. L., Chetty R. et al. Increased resistin gene and protein expression in human abdominal adipose tissue // J. Clin. Endocrinol. Metab. 2002. Vol. 87. P. 2407-2410.
  56. Mehnert H, Kuhlmann H. Hypertonie und Diabetes mellitus // Dtsch. Med. Wschr. 1968. Vol. 19. P. 567-571.
  57. Okamoto Y, Kihara S., Ouchi N. et al. Adiponectin reduces atherosclerosis in apolipoprotein К-deficient mice // Circulation. 2002. Vol. 26. P. 2767-2770.
  58. Ouchi N., Kihara S., Arita Y et al. Adiponectin, adipocyte-derived plasma protein, inhibits endothelial NF-кВ signaling through cAMP-dependent pathway // Circulation. 2000. Vol. 102. P. 1296-1301.
  59. Ouchi N., Kihara S., Arita Y. et al. Novel modulator for endothelial adhesion molecules: adipocyte-derived plasma protein // Circulation. 1999. Vol. 100. P. 2473-2476.
  60. Ouchi N, Kobayashi H., Kihara S. et al. Adiponectin stimulates angiogenesis by promoting cross-talk between AMP-activated protein kinase and Akt signaling in endothelial cells // J. of Biol. Chemistry. 2004. Vol. 279. № 2. P. 1304-1309.
  61. Pallett A. L., Morton N. M., Cawthorne M. A., Emilsson V. Leptin inhibits insulin secretion and reduces insulin mRNA levels in rat isolated pancreatic islets // Biochem. Biophys. Res. Commun. 1997. Vol. 3 8. P. 267-270.
  62. Paolisso G., Rizzo M. R., Mazziotti G. et al. Advancing age and insulin resistance: role of plasma tumor necrosis factor-alpha // Am. J. Physiol. 1998. Vol. 275. P. 294-299.
  63. Park Y. W., Zhu S., Palaniappan L. et al. The metabolic syndrome: Prevalence and associated risk factor findings in the US population from the Third National Health and Nutrition Examination Survey, 1988-1994 // Arch. Intern. Med. 2003. Vol. 163. P. 427-436.
  64. Pischon T., Girman C. J., Hotamisligil G. S. et al. Plasma adiponectin levels and risk of myocardial infarction in men // JAMA. 2004. Vol. 291. P. 1709-1710.
  65. Pyorola K„ Savolainen S. Insulin as a coronary heart disease risk factor: relationship to other risk factors and predictive value during nine and half years follow up of the Helsinki policemen study population // Acta Med. Scand. 1985. Vol. 701. P. 38-52.
  66. Rahmouni K, Haynes W. G., Morgan D. A., Mark A. L. Selective resistance to central neural administration of leptin in Agouti obese mice (part 2) // Hypertension. 2002. Vol. 39. P. 486-490.
  67. Reaven G. M. Banting Lecture: Role of insulin resistance in human disease // Diabetes. 1988. Vol. 37. P. 1595-1607.
  68. Samad F, Loskuttof D. J. Elevated expression of transforming growth factor-β in adipose tissue from obese mice // Mol. Med. 1996. Vol. 2. P. 568-582.
  69. Schirmer S. H, Buschmann I. R., Jost M. M. et al. Differential effects of MCP-1 and leptin on collateral flow and arteriogenesis // Cardiovasc. Res. 2004. Vol. 64. № 2. P. 356-364.
  70. Shibata R., Ouchi N., Ito M. et al. Adiponectin- mediated modulation of hypertrophic signals in the heart // Nat. Med. 2004. Vol. 10. № 1. P. 1384-1389.
  71. Shimomura L, Hammer R. E., Ikemoto S. et al. Leptin reverses insulin resistance and diabetes mellitus in mice with congenital lipodystrophy // Nature. 1999. Vol. 401. P. 73-76.
  72. Sierra-Honigmann М. R., Nath А. К., Murakami С. et al. Biological action of leptin as an angiogenic factor // Science. 1998. Vol. 281. P. 1683-1686.
  73. Sobel В. E. Altered fibrinolysis and platelet function in the development of vascular complications of diabetes // Curr. Opin. Endocrinol. Diabetes. 1996. Vol. 3. P. 3 55-3 60.
  74. St-Pierre A. C., Ruel I. L., Cantin B. et al. Comparison of various electrophoretic characteristics of LDL particles and their relationship to the risk of ischemic heart disease // Circulation. 2001. Vol. 104. P. 2295-2299.
  75. Szanto L, Kahn C. R. Selective interaction between leptin and insulin signaling pathways in a hepatic cell line // Proc. Natl. Acad. Sci. USA. 2000. Vol. 97. P. 2355-2360.
  76. Takahashi M., Arita Y., Yamagata K. et al. Genomic structure and mutations in adipose-specific gene, adiponectin // Inti. J. Obes. 2000. Vol. 24. P. 861-868.
  77. Tanabe K, Okuya S., Tanizawa Y et al. Leptin induces proliferation of pancreatic beta cell line MIN6 through activation of mitogen-activated protein kinase // Biochem. Biophys. Res. Commun. 1997. Vol. 241. P. 765-768.
  78. Valdez R., Athens M. A., Thompson G. H et al. Birth weight and adult health outcomes in a biethnic population in the USA // Diabetologia. 1994. Vol. 3 7. P. 624-631.
  79. VIassara H., Bucala R., Striker L. Pathogenic effects of advanced glycosylation // Lab. Invest. 1994. Vol. 70. P. 138-151.
  80. World Health Organization (WHO). Definition, diagnosis and classification of diabetes mellitus and its complications. Report of a WHO Consultation, part 1: diagnosis and classification of diabetes mellitus. Geneva. Switzerland. WHO. 1999.
  81. Yokota T., Oritani K., Takahashi I. et al. Adiponectin, a new member of the family of soluble defense collagens, negatively regulates the growth of myelomonocytic progenitors and the functions of macrophages // Blood. 2000. Vol. 96. P. 1723-1732.
  82. Yudkin J. S., Eringa E., Stehouwer C. D. «Vasocrine» signaling from perivascular fat: a mechanism linking insulin resistance to vascular disease // Lancet. 2005. Vol. 365. P. 1817-1820.
  83. Yudkin J. S., Kumari M., Humphries S. E., Mohammed-Ali V. Inflammation, obesity, stress and coronary heart disease: is interleukin-6 the link? // Atherosclerosis. 2000. Vol. 148. P. 209-214.
  84. Zhang Y., Proenca R., Maffei M. et al. Positional cloning of the mouse obese gene and its human homologue //Nature. 1994. Vol. 3 72. P. 425-432.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2007 Eco-Vector


СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77 - 74760 от 29.12.2018 г.